GNI Group (TYO:2160) said its subsidiary Gyre Therapeutics has begun dosing in a Phase 1 trial of F230, a treatment candidate for pulmonary arterial hypertension (PAH), in China, according to a Wednesday filing on the Tokyo Stock Exchange.
F230, a selective endothelin A receptor antagonist originally developed by Eisai, was licensed to GNI in 2020. The trial will assess safety, tolerability, and pharmacokinetics in healthy volunteers.
GNI said the move expands Gyre's fibrosis-focused pipeline, which includes lead drug Hydronidone, into cardiovascular disease.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.